SG11201901672RA - Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan - Google Patents
Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetanInfo
- Publication number
- SG11201901672RA SG11201901672RA SG11201901672RA SG11201901672RA SG11201901672RA SG 11201901672R A SG11201901672R A SG 11201901672RA SG 11201901672R A SG11201901672R A SG 11201901672RA SG 11201901672R A SG11201901672R A SG 11201901672RA SG 11201901672R A SG11201901672R A SG 11201901672RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- lilotomab
- pct
- arm
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
2 - 3,5 1-1 00 2 3 0 2 1,5 0:1) 1 Q 0,5 0 0 • Tumor dose n RM dose (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 22 March 2018 (22.03.2018) WI P0 I Iiiimmomiolollmonoloolmoollmunflovoimill (10) International Publication Number WO 2018/050851 Al PCT (51) International Patent Classification: C07K 16/28 (2006.01) A61K 39/395 (2006.01) C07K 16/30 (2006.01) A61P 35/00 (2006.01) A61K 51/10 (2006.01) (21) International Application Number: PCT/EP2017/073336 (22) International Filing Date: 15 September 2017 (15.09.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 16189191.6 16 September 2016 (16.09.2016) EP 17164164.0 31 March 2017 (31.03.2017) EP 17170641.9 11 May 2017 (11.05.2017) EP 17175768.5 13 June 2017 (13.06.2017) EP (71) Applicant: NORDIC NANOVECTOR ASA [NO/NO]; Kjelsasveien 168B, 0884 Oslo (NO). (72) Inventors: DAHLE, Jostein; Vallerveien 106 A, 1344 Haslum (NO). TURNER, Simon; c/o Nordic Nanovector ASA, Kjelsasveien 168 B, 0884 Oslo (NO). (74) Agent: AERA A/S; Gammel Kongevej 60, 18th floor, DK-1850 Frederiksberg C (DK). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (54) Title: TREATMENT OF NON-HODGKIN LYMPHOMA USING LILOTOMAB AND 177LU-LILOTOMAB SATETRAXE- TAN Figure 12 Absorbed radiation dose to tumor and red marrow Arm 1 Arm 4 Arm 2+3 c (57) : The disclosure relates to the use of Lu-lilotomab satetraxetan in the treatment of Non-Hodgkin lymphoma. Aspects 177 included are specific administration patterns, with specific concentrations, pre-treatments and predosing.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16189191 | 2016-09-16 | ||
| EP17164164 | 2017-03-31 | ||
| EP17170641 | 2017-05-11 | ||
| EP17175768 | 2017-06-13 | ||
| PCT/EP2017/073336 WO2018050851A1 (en) | 2016-09-16 | 2017-09-15 | Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901672RA true SG11201901672RA (en) | 2019-03-28 |
Family
ID=59895313
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901672RA SG11201901672RA (en) | 2016-09-16 | 2017-09-15 | Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan |
| SG10202102588QA SG10202102588QA (en) | 2016-09-16 | 2017-09-15 | Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202102588QA SG10202102588QA (en) | 2016-09-16 | 2017-09-15 | Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20190192703A1 (en) |
| EP (1) | EP3512881A1 (en) |
| JP (1) | JP2019529433A (en) |
| KR (1) | KR20190054113A (en) |
| CN (1) | CN109790219A (en) |
| AU (1) | AU2017327772A1 (en) |
| BR (1) | BR112019004838A2 (en) |
| CA (1) | CA3035268A1 (en) |
| IL (1) | IL265387A (en) |
| MX (1) | MX2019003029A (en) |
| PH (1) | PH12019550033A1 (en) |
| RU (1) | RU2019110955A (en) |
| SG (2) | SG11201901672RA (en) |
| WO (1) | WO2018050851A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11130756B2 (en) * | 2017-08-04 | 2021-09-28 | Bristol-Myers Squibb Company | [1,2,4]Triazolo[4,3-A]pyridinyl substituted indole compounds |
| EP3713607A1 (en) * | 2017-11-22 | 2020-09-30 | Nordic Nanovector ASA | Radioimmunoconjugates in combination with other drugs as treatment against nhl |
| KR20240083769A (en) | 2022-12-05 | 2024-06-12 | 김원석 | Water bottle for portable seawater purification unit |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100389825C (en) * | 1999-08-11 | 2008-05-28 | 拜奥根Idec公司 | Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-CD20 antibodies |
| NO331080B1 (en) * | 2010-01-29 | 2011-09-26 | Nordic Nanovector As | Radioimmune conjugates, pharmaceutical compositions and kits comprising the same and their use |
| CN104114192A (en) * | 2011-12-13 | 2014-10-22 | 诺帝克纳诺维科特公司 | Chimeric therapeutic anti-CD37 antibodie HH1 |
| CN108064283B (en) * | 2015-02-24 | 2024-01-09 | 加利福尼亚大学董事会 | Binding triggered transcription switches and methods of use thereof |
-
2017
- 2017-09-15 US US16/329,661 patent/US20190192703A1/en not_active Abandoned
- 2017-09-15 CA CA3035268A patent/CA3035268A1/en active Pending
- 2017-09-15 KR KR1020197010585A patent/KR20190054113A/en not_active Application Discontinuation
- 2017-09-15 SG SG11201901672RA patent/SG11201901672RA/en unknown
- 2017-09-15 AU AU2017327772A patent/AU2017327772A1/en not_active Abandoned
- 2017-09-15 CN CN201780055437.7A patent/CN109790219A/en active Pending
- 2017-09-15 BR BR112019004838A patent/BR112019004838A2/en not_active IP Right Cessation
- 2017-09-15 SG SG10202102588QA patent/SG10202102588QA/en unknown
- 2017-09-15 MX MX2019003029A patent/MX2019003029A/en unknown
- 2017-09-15 JP JP2019515291A patent/JP2019529433A/en active Pending
- 2017-09-15 RU RU2019110955A patent/RU2019110955A/en unknown
- 2017-09-15 WO PCT/EP2017/073336 patent/WO2018050851A1/en unknown
- 2017-09-15 EP EP17768448.7A patent/EP3512881A1/en not_active Withdrawn
-
2019
- 2019-03-07 PH PH12019550033A patent/PH12019550033A1/en unknown
- 2019-03-14 IL IL265387A patent/IL265387A/en unknown
-
2021
- 2021-06-22 US US17/304,541 patent/US20220160907A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN109790219A (en) | 2019-05-21 |
| SG10202102588QA (en) | 2021-04-29 |
| KR20190054113A (en) | 2019-05-21 |
| BR112019004838A2 (en) | 2019-06-04 |
| AU2017327772A1 (en) | 2019-03-21 |
| JP2019529433A (en) | 2019-10-17 |
| US20220160907A1 (en) | 2022-05-26 |
| RU2019110955A3 (en) | 2020-11-26 |
| EP3512881A1 (en) | 2019-07-24 |
| RU2019110955A (en) | 2020-10-20 |
| US20190192703A1 (en) | 2019-06-27 |
| PH12019550033A1 (en) | 2019-07-29 |
| WO2018050851A1 (en) | 2018-03-22 |
| MX2019003029A (en) | 2019-09-13 |
| IL265387A (en) | 2019-05-30 |
| CA3035268A1 (en) | 2018-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201806340YA (en) | Zika virus vaccine | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201907846VA (en) | Therapeutic rna | |
| SG11201908131RA (en) | Benzazepine compounds, conjugates, and uses thereof | |
| SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
| SG11201903021WA (en) | Anti-human 4-1 bb antibodies and use thereof | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201806515RA (en) | Eribulin-based antibody-drug conjugates and methods of use | |
| SG11201806342SA (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201901986SA (en) | Process for the manufacture of a solid pharmaceutical adminstration form | |
| SG11202000494UA (en) | Drug delivery composition | |
| SG11201900361RA (en) | Methods of treating prostate cancer | |
| SG11201805311XA (en) | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion | |
| SG11201809100QA (en) | Use of gram negative species to treat atopic dermatitis | |
| SG11201908602UA (en) | Combination therapy for the treatment of solid and hematological cancers | |
| SG11201907196YA (en) | Composition and methods for preventing radiation injury and promoting tissue regeneration | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201808592PA (en) | Method for selection of high m6p recombinant proteins |